Upregulation of vascular endothelial growth factor (VEGF), its role in progression and prognosis of non-small cell lung carcinoma

• Published in: Cancer genetics 2017-10, Vol.216-217, p.67-73
• Main Authors: Naikoo, Niyaz A., Rasool, Roohi, Shah, Sonaullah, Ahangar, A.G., Siddiqi, Mushtaq A., Shah, Zafar A.
• Format: Article
• Language: English
• Subjects: Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - surgery; Case-Control Studies; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Linear Models; Lung Neoplasms - genetics; Lung Neoplasms - surgery; Male; Middle Aged; Multivariate Analysis; NSCLC; Postoperative Care; Prognosis; progression; RNA, Messenger - genetics; RNA, Messenger - metabolism; Up-Regulation - genetics; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor A - metabolism; VEGF
• ISSN: 2210-7762; 2210-7770
• DOI: 10.1016/j.cancergen.2017.07.005

•Significant association of VEGF mRNA with advanced clinical stages and adenocarcinoma histology in NSCLC.•VEGF mRNA (−ΔCT ≥10) was found to be associated with NSCLC.•Quantity of VEGF mRNA can be useful to predict the progression of NSCLC. Elevated VEGF mRNA (−ΔCT) was significantly associated with adenocarcinoma histology (vs squamous) and advanced NSCLC clinical stages in a univariable analysis; however, this association did not remain significant in the multivariable analysis. Of interest, a Kaplan–Meier analysis showed that NSCLC patients with higher VEGF mRNA (−ΔCT ≥10) had a significantly poorer overall survival and shorter postoperative relapse time in adenocarcinoma and in stage III/IV than those with VEGF mRNA of −ΔCT